Mavyret

Overview

glecaprevir

direct-acting antiviral

• CYP3A4 substrate
• BCRP substrate
• OATP1B1 substrate
• OATP1B3 substrate
• P-gp substrate
• CYP1A2 inhibitor, weak
• CYP3A4 inhibitor, weak
• BCRP inhibitor
• OATP1B1 inhibitor, moderate
• OATP1B3 inhibitor, moderate
• P-gp inhibitor, strong

• caution advised w/ narrow therapeutic index drugs extensively metabolized in the liver; viral eradication may improve hepatic metabolic function, decr. levels, efficacy of concomitant drugs
• monitor glucose w/ drugs used for diabetes tx; viral eradication may change hepatic function, alter blood glucose control resulting in serious symptomatic hypoglycemia

pibrentasvir

direct-acting antiviral

• BCRP substrate
• P-gp substrate
• CYP1A2 inhibitor, weak
• CYP3A4 inhibitor, weak
• BCRP inhibitor
• OATP1B1 inhibitor, moderate
• OATP1B3 inhibitor, moderate
• P-gp inhibitor, strong

• caution advised w/ narrow therapeutic index drugs extensively metabolized in the liver; viral eradication may improve hepatic metabolic function, decr. levels, efficacy of concomitant drugs
• monitor glucose w/ drugs used for diabetes tx; viral eradication may change hepatic function, alter blood glucose control resulting in serious symptomatic hypoglycemia

Contraindicated

• atazanavir
Mavyret (glecaprevir/ pibrentasvir)

+

atazanavir

2 interactions

Contraindicated

glecaprevir + atazanavir

contraindicated: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited)

pibrentasvir + atazanavir

contraindicated: combo may incr. pibrentasvir levels, risk of adverse effects (mechanism unknown)

• cisapride
Mavyret (glecaprevir/ pibrentasvir)

+

cisapride

2 interactions

Contraindicated

glecaprevir + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• colchicine
Mavyret (glecaprevir/ pibrentasvir)

+

colchicine

2 interactions

Contraindicated

glecaprevir + colchicine

CV RISK REDUCTION: contraindicated; GOUT or FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or decr. colchicine dose based on indication during and x14 days after glecaprevir use as follows: GOUT PROPHYLAXIS: give colchicine 0.3 mg qod-qd; ACUTE GOUT TX: give colchicine 0.6 mg x1 only; FMF: decr. max colchicine dose to 0.6 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + colchicine

CV RISK REDUCTION: contraindicated; GOUT or FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or decr. colchicine dose based on indication during and x14 days after pibrentasvir use as follows: GOUT PROPHYLAXIS: give colchicine 0.3 mg qod-qd; ACUTE GOUT TX: give colchicine 0.6 mg x1 only; FMF: decr. max colchicine dose to 0.6 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• elagolix
Mavyret (glecaprevir/ pibrentasvir)

+

elagolix

2 interactions

Contraindicated

glecaprevir + elagolix

contraindicated: combo may incr. elagolix levels, risk of adverse effects; may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited; P-gp-mediated transport inhibited, hepatic metab. induced)

pibrentasvir + elagolix

contraindicated: combo may incr. elagolix levels, risk of adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic transport inhibited; P-gp-mediated transport inhibited)

• eliglustat
Mavyret (glecaprevir/ pibrentasvir)

+

eliglustat

2 interactions

Contraindicated

glecaprevir + eliglustat

CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. levels of both drugs, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + eliglustat

CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. levels of both drugs, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• fezolinetant
Mavyret (glecaprevir/ pibrentasvir)

+

fezolinetant

2 interactions

Contraindicated

glecaprevir + fezolinetant

contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + fezolinetant

contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metab. inhibited)

• grazoprevir
Mavyret (glecaprevir/ pibrentasvir)

+

grazoprevir

2 interactions

Contraindicated

glecaprevir + grazoprevir

contraindicated: combo may incr. levels of both drugs, risk of adverse effects (hepatic transport inhibited, gut BCRP-mediated transport inhibited)

pibrentasvir + grazoprevir

contraindicated: combo may incr. levels of both drugs, risk of adverse effects (hepatic transport inhibited, gut BCRP-mediated transport inhibited)

• rifampin
Mavyret (glecaprevir/ pibrentasvir)

+

rifampin

2 interactions

Contraindicated

glecaprevir + rifampin

contraindicated: combo may decr. glecaprevir levels, efficacy; may incr. rifampin levels, risk of adverse effects (hepatic metab. induced, hepatic transport induced, P-gp-mediated transport induced; hepatic transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + rifampin

contraindicated: combo may decr. pibrentasvir levels, efficacy; may incr. rifampin levels, risk of adverse effects (P-gp-mediated transport induced; hepatic transport inhibited, P-gp-mediated transport inhibited)

Avoid/Use Alternative

• alpelisib
Mavyret (glecaprevir/ pibrentasvir)

+

alpelisib

2 interactions

Avoid/Use Alternative

glecaprevir + alpelisib

use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

pibrentasvir + alpelisib

use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

• alprazolam
Mavyret (glecaprevir/ pibrentasvir)

+

alprazolam

2 interactions

Avoid/Use Alternative

glecaprevir + alprazolam

use alternative or monitor resp. rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

pibrentasvir + alprazolam

use alternative or monitor resp. rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• apalutamide
Mavyret (glecaprevir/ pibrentasvir)

+

apalutamide

2 interactions

Avoid/Use Alternative

glecaprevir + apalutamide

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, BCRP-mediated transport induced, P-gp-mediated transport induced, hepatic transport induced)

Caution Advised

pibrentasvir + apalutamide

caution advised: combo may decr. pibrentasvir levels, efficacy (BCRP-mediated transport induced, P-gp-mediated transport induced)

• apixaban
Mavyret (glecaprevir/ pibrentasvir)

+

apixaban

2 interactions

Avoid/Use Alternative

glecaprevir + apixaban

ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5 mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + apixaban

ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5 mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• atorvastatin
Mavyret (glecaprevir/ pibrentasvir)

+

atorvastatin

2 interactions

Avoid/Use Alternative

glecaprevir + atorvastatin

avoid combo: combo may incr. levels of both drugs, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + atorvastatin

avoid combo: combo may incr. levels of both drugs, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• atrasentan
Mavyret (glecaprevir/ pibrentasvir)

+

atrasentan

2 interactions

Avoid/Use Alternative

glecaprevir + atrasentan

avoid combo: combo may incr. atrasentan levels, risk of adverse effects (hepatic transport inhibited)

pibrentasvir + atrasentan

avoid combo: combo may incr. atrasentan levels, risk of adverse effects (hepatic transport inhibited)

• bosentan
Mavyret (glecaprevir/ pibrentasvir)

+

bosentan

2 interactions

Avoid/Use Alternative

glecaprevir + bosentan

avoid combo: combo may incr. bosentan levels, risk of adverse effects; decr. glecaprevir levels, efficacy (hepatic transport inhibited; hepatic metab. induced)

Caution Advised

pibrentasvir + bosentan

caution advised: combo may incr. bosentan levels, risk of adverse effects (hepatic transport inhibited)

• brincidofovir
Mavyret (glecaprevir/ pibrentasvir)

+

brincidofovir

2 interactions

Avoid/Use Alternative

glecaprevir + brincidofovir

consider alternative or monitor LFTs, GI toxicity sx; give brincidofovir at least 3h before glecaprevir: combo may incr. brincidofovir levels, risk of hepatotoxicity, GI toxicity, other adverse effects (hepatic transport inhibited)

pibrentasvir + brincidofovir

consider alternative or monitor LFTs, GI toxicity sx; give brincidofovir at least 3h before pibrentasvir: combo may incr. brincidofovir levels, risk of hepatotoxicity, GI toxicity, other adverse effects (hepatic transport inhibited)

• butalbital
Mavyret (glecaprevir/ pibrentasvir)

+

butalbital

1 interaction

Avoid/Use Alternative

glecaprevir + butalbital

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• carbamazepine
Mavyret (glecaprevir/ pibrentasvir)

+

carbamazepine

2 interactions

Avoid/Use Alternative

glecaprevir + carbamazepine

avoid combo: combo may incr. carbamazepine levels, risk of adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited; hepatic metab. induced, hepatic transport induced, P-gp-mediated transport induced)

pibrentasvir + carbamazepine

avoid combo: combo may incr. carbamazepine levels, risk of adverse effects; may decr. pibrentasvir levels, efficacy (hepatic metab. inhibited; P-gp-mediated transport induced)

• cenobamate
Mavyret (glecaprevir/ pibrentasvir)

+

cenobamate

1 interaction

Avoid/Use Alternative

glecaprevir + cenobamate

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• cladribine oral
Mavyret (glecaprevir/ pibrentasvir)

+

cladribine oral

2 interactions

Avoid/Use Alternative

glecaprevir + cladribine oral

use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated-transport inhibited)

pibrentasvir + cladribine oral

use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated-transport inhibited)

• codeine
Mavyret (glecaprevir/ pibrentasvir)

+

codeine

2 interactions

Avoid/Use Alternative

glecaprevir + codeine

use alternative or monitor resp. rate, consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite morphine)

pibrentasvir + codeine

use alternative or monitor resp. rate, consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite morphine)

• cyclosporine
Mavyret (glecaprevir/ pibrentasvir)

+

cyclosporine

2 interactions

Avoid/Use Alternative

glecaprevir + cyclosporine

avoid combo if on cyclosporine doses >100 mg/day; otherwise, monitor cyclosporine levels, renal fxn: combo may incr. levels of both drugs, risk of serious infection, nephrotoxicity, other adverse effects (hepatic metab. inhibited, hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + cyclosporine

avoid combo if on cyclosporine doses >100 mg/day; otherwise, monitor cyclosporine levels, renal fxn: combo may incr. levels of both drugs, risk of serious infection, nephrotoxicity, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• dabigatran
Mavyret (glecaprevir/ pibrentasvir)

+

dabigatran

2 interactions

Avoid/Use Alternative

glecaprevir + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited)

• dabrafenib
Mavyret (glecaprevir/ pibrentasvir)

+

dabrafenib

1 interaction

Avoid/Use Alternative

glecaprevir + dabrafenib

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• darunavir
Mavyret (glecaprevir/ pibrentasvir)

+

darunavir

2 interactions

Avoid/Use Alternative

glecaprevir + darunavir

avoid combo: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, hepatic transport inhibited)

pibrentasvir + darunavir

avoid combo: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• doxorubicin
Mavyret (glecaprevir/ pibrentasvir)

+

doxorubicin

2 interactions

Avoid/Use Alternative

glecaprevir + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (P-gp-mediated transport inhibited)

• efavirenz
Mavyret (glecaprevir/ pibrentasvir)

+

efavirenz

2 interactions

Avoid/Use Alternative

glecaprevir + efavirenz

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

pibrentasvir + efavirenz

avoid combo: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport induced)

• encorafenib
Mavyret (glecaprevir/ pibrentasvir)

+

encorafenib

2 interactions

Avoid/Use Alternative

glecaprevir + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. inhibited; BCRP-mediated transport inhibited, hepatic transport inhibited, hepatic metab. induced)

Monitor/Modify Tx

pibrentasvir + encorafenib

monitor ECG: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; BCRP-mediated transport inhibited)

• ensartinib
Mavyret (glecaprevir/ pibrentasvir)

+

ensartinib

2 interactions

Avoid/Use Alternative

glecaprevir + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

pibrentasvir + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

• enzalutamide
Mavyret (glecaprevir/ pibrentasvir)

+

enzalutamide

2 interactions

Avoid/Use Alternative

glecaprevir + enzalutamide

avoid combo: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

Caution Advised

pibrentasvir + enzalutamide

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• ethinyl estradiol (contraceptive)
Mavyret (glecaprevir/ pibrentasvir)

+

ethinyl estradiol (contraceptive)

2 interactions

Avoid/Use Alternative

glecaprevir + ethinyl estradiol (contraceptive)

avoid combo if ethinyl estradiol dose >20 mcg/day: combo may incr. risk of ALT elevation (additive effects)

pibrentasvir + ethinyl estradiol (contraceptive)

avoid combo if ethinyl estradiol dose >20 mcg/day: combo may incr. risk of ALT elevation (additive effects)

• etravirine
Mavyret (glecaprevir/ pibrentasvir)

+

etravirine

2 interactions

Avoid/Use Alternative

glecaprevir + etravirine

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

pibrentasvir + etravirine

avoid combo: combo may decr. pibrentasvir levels, efficacy (mechanism unknown)

• fedratinib
Mavyret (glecaprevir/ pibrentasvir)

+

fedratinib

2 interactions

Avoid/Use Alternative

glecaprevir + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, avoid combo; otherwise, caution advised: combo may incr. fedratinib levels, risk myelosuppression, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

Monitor/Modify Tx

pibrentasvir + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs: combo may incr. fedratinib levels, risk myelosuppression, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• fexinidazole
Mavyret (glecaprevir/ pibrentasvir)

+

fexinidazole

2 interactions

Avoid/Use Alternative

glecaprevir + fexinidazole

avoid combo: combo may decr. glecaprevir levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy (hepatic metab. induced; hepatic metab. inhibited, decr. conversion to active metabolites)

Caution Advised

pibrentasvir + fexinidazole

caution advised: combo may decr. fexinidazole active metabolite levels, efficacy (hepatic metab. inhibited, decr. conversion to active metabolites)

• fosphenytoin
Mavyret (glecaprevir/ pibrentasvir)

+

fosphenytoin

2 interactions

Avoid/Use Alternative

glecaprevir + fosphenytoin

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

pibrentasvir + fosphenytoin

avoid combo: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport induced)

• futibatinib
Mavyret (glecaprevir/ pibrentasvir)

+

futibatinib

2 interactions

Avoid/Use Alternative

glecaprevir + futibatinib

avoid combo if also combined w/ strong CYP3A4 inhibitor; otherwise, monitor phosphate: combo may incr. levels of both drugs, risk of hyperphosphatemia, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + futibatinib

avoid combo if also combined w/ strong CYP3A4 inhibitor; otherwise, monitor phosphate: combo may incr. levels of both drugs, risk of hyperphosphatemia, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• hydrocodone
Mavyret (glecaprevir/ pibrentasvir)

+

hydrocodone

2 interactions

Avoid/Use Alternative

glecaprevir + hydrocodone

use alternative or monitor resp. rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + hydrocodone

use alternative or monitor resp. rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ivosidenib
Mavyret (glecaprevir/ pibrentasvir)

+

ivosidenib

2 interactions

Avoid/Use Alternative

glecaprevir + ivosidenib

avoid combo: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

Monitor/Modify Tx

pibrentasvir + ivosidenib

monitor ECG: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• lefamulin
Mavyret (glecaprevir/ pibrentasvir)

+

lefamulin

2 interactions

Avoid/Use Alternative

glecaprevir + lefamulin

ORAL LEFAMULIN: avoid combo; IV lefamulin use OK: combo may incr. lefamulin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + lefamulin

ORAL LEFAMULIN: avoid combo; IV lefamulin use OK: combo may incr. lefamulin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• lenacapavir
Mavyret (glecaprevir/ pibrentasvir)

+

lenacapavir

2 interactions

Avoid/Use Alternative

glecaprevir + lenacapavir

avoid combo if also combined w/ strong CYP3A4 and UGT1A1 inhibitors; otherwise, caution advised: combo may incr. levels of both drugs, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + lenacapavir

avoid combo if also combined w/ strong CYP3A4 and UGT1A1 inhibitors; otherwise, caution advised: combo may incr. levels of both drugs, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• lopinavir/ritonavir
Mavyret (glecaprevir/ pibrentasvir)

+

lopinavir/ ritonavir

2 interactions

Avoid/Use Alternative

glecaprevir + lopinavir/ ritonavir

avoid combo: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited, hepatic transport inhibited)

pibrentasvir + lopinavir/ ritonavir

avoid combo: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• lorlatinib
Mavyret (glecaprevir/ pibrentasvir)

+

lorlatinib

2 interactions

Avoid/Use Alternative

glecaprevir + lorlatinib

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

Caution Advised

pibrentasvir + lorlatinib

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport induced)

• lovastatin
Mavyret (glecaprevir/ pibrentasvir)

+

lovastatin

2 interactions

Avoid/Use Alternative

glecaprevir + lovastatin

avoid combo: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, hepatic transport inhibited)

pibrentasvir + lovastatin

avoid combo: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, hepatic transport inhibited)

• lumacaftor/ivacaftor
Mavyret (glecaprevir/ pibrentasvir)

+

lumacaftor/ ivacaftor

2 interactions

Avoid/Use Alternative

glecaprevir + lumacaftor/ ivacaftor

avoid combo: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. induced, P-gp-mediated transport possibly altered)

Caution Advised

pibrentasvir + lumacaftor/ ivacaftor

caution advised: combo may incr. or decr. pibrentasvir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport possibly altered)

• mavacamten
Mavyret (glecaprevir/ pibrentasvir)

+

mavacamten

2 interactions

Avoid/Use Alternative

glecaprevir + mavacamten

avoid combo: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

Monitor/Modify Tx

pibrentasvir + mavacamten

monitor cardiac fxn, incl. LVEF: combo may incr. mavacamten levels, risk of heart failure, other adverse effects (hepatic metab. inhibited)

• meperidine
Mavyret (glecaprevir/ pibrentasvir)

+

meperidine

2 interactions

Avoid/Use Alternative

glecaprevir + meperidine

use alternative or monitor resp. rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + meperidine

use alternative or monitor resp. rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• methadone
Mavyret (glecaprevir/ pibrentasvir)

+

methadone

2 interactions

Avoid/Use Alternative

glecaprevir + methadone

use alternative or monitor resp. rate, ECG, consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + methadone

use alternative or monitor resp. rate, ECG, consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• mitapivat
Mavyret (glecaprevir/ pibrentasvir)

+

mitapivat

2 interactions

Avoid/Use Alternative

glecaprevir + mitapivat

avoid combo: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metab. induced)

Caution Advised

pibrentasvir + mitapivat

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• mitotane
Mavyret (glecaprevir/ pibrentasvir)

+

mitotane

1 interaction

Avoid/Use Alternative

glecaprevir + mitotane

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• modafinil
Mavyret (glecaprevir/ pibrentasvir)

+

modafinil

1 interaction

Avoid/Use Alternative

glecaprevir + modafinil

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• nafcillin
Mavyret (glecaprevir/ pibrentasvir)

+

nafcillin

1 interaction

Avoid/Use Alternative

glecaprevir + nafcillin

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• neratinib
Mavyret (glecaprevir/ pibrentasvir)

+

neratinib

2 interactions

Avoid/Use Alternative

glecaprevir + neratinib

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. levels of both drugs, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + neratinib

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. levels of both drugs, risk of adverse effects (P-gp-mediated transport inhibited)

• nevirapine
Mavyret (glecaprevir/ pibrentasvir)

+

nevirapine

1 interaction

Avoid/Use Alternative

glecaprevir + nevirapine

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• oxycodone
Mavyret (glecaprevir/ pibrentasvir)

+

oxycodone

2 interactions

Avoid/Use Alternative

glecaprevir + oxycodone

use alternative or monitor resp. rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

pibrentasvir + oxycodone

use alternative or monitor resp. rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• pacritinib
Mavyret (glecaprevir/ pibrentasvir)

+

pacritinib

2 interactions

Avoid/Use Alternative

glecaprevir + pacritinib

avoid combo: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy; may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited, hepatic metab. induced; hepatic metab. inhibited)

Monitor/Modify Tx

pibrentasvir + pacritinib

monitor ECG, CBC, bleeding s/sx: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (incl. life-threatening), other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• pazopanib
Mavyret (glecaprevir/ pibrentasvir)

+

pazopanib

2 interactions

Avoid/Use Alternative

glecaprevir + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• pentobarbital
Mavyret (glecaprevir/ pibrentasvir)

+

pentobarbital

1 interaction

Avoid/Use Alternative

glecaprevir + pentobarbital

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• pexidartinib
Mavyret (glecaprevir/ pibrentasvir)

+

pexidartinib

2 interactions

Avoid/Use Alternative

glecaprevir + pexidartinib

avoid combo: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

Caution Advised

pibrentasvir + pexidartinib

caution advised: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• phenobarbital
Mavyret (glecaprevir/ pibrentasvir)

+

phenobarbital

2 interactions

Avoid/Use Alternative

glecaprevir + phenobarbital

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced; P-gp-mediated transport possibly induced)

Caution Advised

pibrentasvir + phenobarbital

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport possibly induced)

• phenytoin
Mavyret (glecaprevir/ pibrentasvir)

+

phenytoin

2 interactions

Avoid/Use Alternative

glecaprevir + phenytoin

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

pibrentasvir + phenytoin

avoid combo: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport induced)

• pimozide
Mavyret (glecaprevir/ pibrentasvir)

+

pimozide

2 interactions

Avoid/Use Alternative

glecaprevir + pimozide

use alternative or monitor ECG: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + pimozide

use alternative or monitor ECG: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• pralsetinib
Mavyret (glecaprevir/ pibrentasvir)

+

pralsetinib

2 interactions

Avoid/Use Alternative

glecaprevir + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• primidone
Mavyret (glecaprevir/ pibrentasvir)

+

primidone

2 interactions

Avoid/Use Alternative

glecaprevir + primidone

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly induced)

Caution Advised

pibrentasvir + primidone

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport possibly induced)

• propafenone
Mavyret (glecaprevir/ pibrentasvir)

+

propafenone

2 interactions

Avoid/Use Alternative

glecaprevir + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• relugolix
Mavyret (glecaprevir/ pibrentasvir)

+

relugolix

2 interactions

Avoid/Use Alternative

glecaprevir + relugolix

PROSTATE CANCER: may hold relugolix if glecaprevir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before glecaprevir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before glecaprevir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

pibrentasvir + relugolix

PROSTATE CANCER: may hold relugolix if pibrentasvir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before pibrentasvir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before pibrentasvir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• repotrectinib
Mavyret (glecaprevir/ pibrentasvir)

+

repotrectinib

2 interactions

Avoid/Use Alternative

glecaprevir + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

pibrentasvir + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• resmetirom
Mavyret (glecaprevir/ pibrentasvir)

+

resmetirom

2 interactions

Avoid/Use Alternative

glecaprevir + resmetirom

avoid combo: combo may incr. levels of both drugs, risk of adverse effects (hepatic transport possibly inhibited, BCRP-mediated transport inhibited)

pibrentasvir + resmetirom

avoid combo: combo may incr. levels of both drugs, risk of adverse effects (hepatic transport possibly inhibited, BCRP-mediated transport inhibited)

• rifabutin
Mavyret (glecaprevir/ pibrentasvir)

+

rifabutin

2 interactions

Avoid/Use Alternative

glecaprevir + rifabutin

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly induced)

Caution Advised

pibrentasvir + rifabutin

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport possibly induced)

• rifapentine
Mavyret (glecaprevir/ pibrentasvir)

+

rifapentine

2 interactions

Avoid/Use Alternative

glecaprevir + rifapentine

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced; P-gp-mediated transport possibly induced)

Caution Advised

pibrentasvir + rifapentine

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport possibly induced)

• ritonavir
Mavyret (glecaprevir/ pibrentasvir)

+

ritonavir

2 interactions

Avoid/Use Alternative

glecaprevir + ritonavir

avoid combo: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + ritonavir

avoid combo: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• rivaroxaban
Mavyret (glecaprevir/ pibrentasvir)

+

rivaroxaban

2 interactions

Avoid/Use Alternative

glecaprevir + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• silodosin
Mavyret (glecaprevir/ pibrentasvir)

+

silodosin

2 interactions

Avoid/Use Alternative

glecaprevir + silodosin

avoid combo: combo may incr. silodosin levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + silodosin

avoid combo: combo may incr. silodosin levels, risk of adverse effects (P-gp-mediated transport inhibited)

• simvastatin
Mavyret (glecaprevir/ pibrentasvir)

+

simvastatin

2 interactions

Avoid/Use Alternative

glecaprevir + simvastatin

avoid combo: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + simvastatin

avoid combo: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• sirolimus
Mavyret (glecaprevir/ pibrentasvir)

+

sirolimus

2 interactions

Avoid/Use Alternative

glecaprevir + sirolimus

use alternative or monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + sirolimus

use alternative or monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• sirolimus albumin-bound
Mavyret (glecaprevir/ pibrentasvir)

+

sirolimus albumin-bound

2 interactions

Avoid/Use Alternative

glecaprevir + sirolimus albumin-bound

avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + sirolimus albumin-bound

avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• sotorasib
Mavyret (glecaprevir/ pibrentasvir)

+

sotorasib

2 interactions

Avoid/Use Alternative

glecaprevir + sotorasib

avoid combo: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited, hepatic metab. induced)

Caution Advised

pibrentasvir + sotorasib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• St. John's wort
Mavyret (glecaprevir/ pibrentasvir)

+

St. John's wort

2 interactions

Avoid/Use Alternative

glecaprevir + St. John's wort

avoid combo: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

pibrentasvir + St. John's wort

avoid combo: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport induced)

• tepotinib
Mavyret (glecaprevir/ pibrentasvir)

+

tepotinib

2 interactions

Avoid/Use Alternative

pibrentasvir + tepotinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

Caution Advised

glecaprevir + tepotinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• tizanidine
Mavyret (glecaprevir/ pibrentasvir)

+

tizanidine

2 interactions

Avoid/Use Alternative

glecaprevir + tizanidine

use alternative or monitor BP, HR: combo may incr. tizanidine levels, risk of hypotension (incl. orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

pibrentasvir + tizanidine

use alternative or monitor BP, HR: combo may incr. tizanidine levels, risk of hypotension (incl. orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• topotecan
Mavyret (glecaprevir/ pibrentasvir)

+

topotecan

2 interactions

Avoid/Use Alternative

glecaprevir + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited)

pibrentasvir + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited)

• venetoclax
Mavyret (glecaprevir/ pibrentasvir)

+

venetoclax

2 interactions

Avoid/Use Alternative

glecaprevir + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; give glecaprevir at least 6h before venetoclax: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; give pibrentasvir at least 6h before venetoclax: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• voxilaprevir
Mavyret (glecaprevir/ pibrentasvir)

+

voxilaprevir

2 interactions

Avoid/Use Alternative

glecaprevir + voxilaprevir

avoid combo: combo may incr. levels of both drugs, risk of adverse effects (hepatic transport inhibited, gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited)

pibrentasvir + voxilaprevir

avoid combo: combo may incr. levels of both drugs, risk of adverse effects (hepatic transport inhibited, gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited)

• zavegepant
Mavyret (glecaprevir/ pibrentasvir)

+

zavegepant

2 interactions

Avoid/Use Alternative

glecaprevir + zavegepant

avoid combo: combo may incr. zavegepant levels, risk of adverse effects (hepatic transport inhibited)

pibrentasvir + zavegepant

avoid combo: combo may incr. zavegepant levels, risk of adverse effects (hepatic transport inhibited)

Monitor/Modify Tx

• abemaciclib
Mavyret (glecaprevir/ pibrentasvir)

+

abemaciclib

2 interactions

Monitor/Modify Tx

glecaprevir + abemaciclib

monitor CBC: combo may incr. abemaciclib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

pibrentasvir + abemaciclib

monitor CBC: combo may incr. abemaciclib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• acalabrutinib
Mavyret (glecaprevir/ pibrentasvir)

+

acalabrutinib

2 interactions

Monitor/Modify Tx

glecaprevir + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; gut BCRP-mediated transport possibly inhibited)

pibrentasvir + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; gut BCRP-mediated transport possibly inhibited)

• afatinib
Mavyret (glecaprevir/ pibrentasvir)

+

afatinib

2 interactions

Monitor/Modify Tx

glecaprevir + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• alfentanil
Mavyret (glecaprevir/ pibrentasvir)

+

alfentanil

2 interactions

Monitor/Modify Tx

glecaprevir + alfentanil

monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + alfentanil

monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

• aminophylline
Mavyret (glecaprevir/ pibrentasvir)

+

aminophylline

2 interactions

Monitor/Modify Tx

glecaprevir + aminophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metab. inhibited; aminophylline converted to theophylline)

pibrentasvir + aminophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metab. inhibited; aminophylline converted to theophylline)

• amiodarone
Mavyret (glecaprevir/ pibrentasvir)

+

amiodarone

2 interactions

Monitor/Modify Tx

glecaprevir + amiodarone

monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + amiodarone

monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• atogepant
Mavyret (glecaprevir/ pibrentasvir)

+

atogepant

2 interactions

Monitor/Modify Tx

glecaprevir + atogepant

adjust max atogepant dose to 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

pibrentasvir + atogepant

adjust max atogepant dose to 30 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic transport inhibited)

• avanafil
Mavyret (glecaprevir/ pibrentasvir)

+

avanafil

2 interactions

Monitor/Modify Tx

glecaprevir + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

pibrentasvir + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avapritinib
Mavyret (glecaprevir/ pibrentasvir)

+

avapritinib

2 interactions

Monitor/Modify Tx

glecaprevir + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

pibrentasvir + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• avatrombopag
Mavyret (glecaprevir/ pibrentasvir)

+

avatrombopag

2 interactions

Monitor/Modify Tx

glecaprevir + avatrombopag

monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + avatrombopag

monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (P-gp-mediated transport inhibited)

• bendamustine
Mavyret (glecaprevir/ pibrentasvir)

+

bendamustine

2 interactions

Monitor/Modify Tx

glecaprevir + bendamustine

monitor CBC: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

pibrentasvir + bendamustine

monitor CBC: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• brigatinib
Mavyret (glecaprevir/ pibrentasvir)

+

brigatinib

2 interactions

Monitor/Modify Tx

glecaprevir + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. inhibited; P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited, hepatic metab. induced)

pibrentasvir + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; BCRP-mediated transport possibly inhibited, P-gp-mediated transport possibly inhibited)

• caffeine citrate
Mavyret (glecaprevir/ pibrentasvir)

+

caffeine citrate

2 interactions

Monitor/Modify Tx

glecaprevir + caffeine citrate

monitor caffeine levels: combo may incr. caffeine levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + caffeine citrate

monitor caffeine levels: combo may incr. caffeine levels, risk of adverse effects (hepatic metab. inhibited)

• capivasertib
Mavyret (glecaprevir/ pibrentasvir)

+

capivasertib

2 interactions

Monitor/Modify Tx

glecaprevir + capivasertib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + capivasertib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• carvedilol
Mavyret (glecaprevir/ pibrentasvir)

+

carvedilol

2 interactions

Monitor/Modify Tx

glecaprevir + carvedilol

monitor BP, HR: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + carvedilol

monitor BP, HR: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• ceritinib
Mavyret (glecaprevir/ pibrentasvir)

+

ceritinib

2 interactions

Monitor/Modify Tx

glecaprevir + ceritinib

monitor ECG, electrolytes: combo may incr. ceritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + ceritinib

monitor ECG, electrolytes: combo may incr. ceritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• clozapine
Mavyret (glecaprevir/ pibrentasvir)

+

clozapine

2 interactions

Monitor/Modify Tx

glecaprevir + clozapine

monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + clozapine

monitor ECG, BP, HR; consider decr. clozapine dos: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metab. inhibited)

• daunorubicin
Mavyret (glecaprevir/ pibrentasvir)

+

daunorubicin

2 interactions

Monitor/Modify Tx

glecaprevir + daunorubicin

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. daunorubicin levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + daunorubicin

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. daunorubicin levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (P-gp-mediated transport inhibited)

• digoxin
Mavyret (glecaprevir/ pibrentasvir)

+

digoxin

2 interactions

Monitor/Modify Tx

glecaprevir + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 50%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 50%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• diltiazem
Mavyret (glecaprevir/ pibrentasvir)

+

diltiazem

2 interactions

Monitor/Modify Tx

glecaprevir + diltiazem

monitor BP, HR: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + diltiazem

monitor BP, HR: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• disopyramide
Mavyret (glecaprevir/ pibrentasvir)

+

disopyramide

2 interactions

Monitor/Modify Tx

glecaprevir + disopyramide

monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + disopyramide

monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• docetaxel
Mavyret (glecaprevir/ pibrentasvir)

+

docetaxel

2 interactions

Monitor/Modify Tx

glecaprevir + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

pibrentasvir + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dofetilide
Mavyret (glecaprevir/ pibrentasvir)

+

dofetilide

2 interactions

Monitor/Modify Tx

glecaprevir + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• domperidone
Mavyret (glecaprevir/ pibrentasvir)

+

domperidone

2 interactions

Monitor/Modify Tx

glecaprevir + domperidone

monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + domperidone

monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• edoxaban
Mavyret (glecaprevir/ pibrentasvir)

+

edoxaban

2 interactions

Monitor/Modify Tx

glecaprevir + edoxaban

monitor bleeding s/sx; decr. edoxaban dose to 30 mg/day in DVT/PE pts; no dose adjustment recommended in atrial fibrillation pts: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + edoxaban

monitor bleeding s/sx; decr. edoxaban dose to 30 mg/day in DVT/PE pts; no dose adjustment recommended in atrial fibrillation pts: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• eluxadoline
Mavyret (glecaprevir/ pibrentasvir)

+

eluxadoline

2 interactions

Monitor/Modify Tx

glecaprevir + eluxadoline

decr. eluxadoline dose to 75 mg bid: combo may incr. levels of both drugs, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + eluxadoline

decr. eluxadoline dose to 75 mg bid: combo may incr. levels of both drugs, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• enfortumab vedotin
Mavyret (glecaprevir/ pibrentasvir)

+

enfortumab vedotin

2 interactions

Monitor/Modify Tx

glecaprevir + enfortumab vedotin

if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + enfortumab vedotin

if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)

• entrectinib
Mavyret (glecaprevir/ pibrentasvir)

+

entrectinib

2 interactions

Monitor/Modify Tx

glecaprevir + entrectinib

monitor ECG, CBC: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + entrectinib

monitor ECG, CBC: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• erdafitinib
Mavyret (glecaprevir/ pibrentasvir)

+

erdafitinib

2 interactions

Monitor/Modify Tx

glecaprevir + erdafitinib

separate admin. by at least 6h: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

pibrentasvir + erdafitinib

separate admin. by at least 6h: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• erythromycin
Mavyret (glecaprevir/ pibrentasvir)

+

erythromycin

2 interactions

Monitor/Modify Tx

glecaprevir + erythromycin

monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited, hepatic transport inhibited)

pibrentasvir + erythromycin

monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• etoposide
Mavyret (glecaprevir/ pibrentasvir)

+

etoposide

2 interactions

Monitor/Modify Tx

glecaprevir + etoposide

monitor CBC: combo may incr. etoposide levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + etoposide

monitor CBC: combo may incr. etoposide levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

• everolimus
Mavyret (glecaprevir/ pibrentasvir)

+

everolimus

2 interactions

Monitor/Modify Tx

glecaprevir + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• felodipine
Mavyret (glecaprevir/ pibrentasvir)

+

felodipine

2 interactions

Monitor/Modify Tx

glecaprevir + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• fentanyl
Mavyret (glecaprevir/ pibrentasvir)

+

fentanyl

2 interactions

Monitor/Modify Tx

glecaprevir + fentanyl

monitor resp. rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

pibrentasvir + fentanyl

monitor resp. rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• finerenone
Mavyret (glecaprevir/ pibrentasvir)

+

finerenone

2 interactions

Monitor/Modify Tx

glecaprevir + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

• flibanserin
Mavyret (glecaprevir/ pibrentasvir)

+

flibanserin

2 interactions

Monitor/Modify Tx

glecaprevir + flibanserin

monitor BP, especially if flibanserin also combined w/ other weak CYP3A4 inhibitors: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + flibanserin

monitor BP, especially if flibanserin also combined w/ other weak CYP3A4 inhibitors: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• fluvastatin
Mavyret (glecaprevir/ pibrentasvir)

+

fluvastatin

2 interactions

Monitor/Modify Tx

glecaprevir + fluvastatin

monitor CK, myopathy sx; use lowest effective fluvastatin dose: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + fluvastatin

monitor CK, myopathy sx; use lowest effective fluvastatin dose: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• gepirone
Mavyret (glecaprevir/ pibrentasvir)

+

gepirone

2 interactions

Monitor/Modify Tx

glecaprevir + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• gilteritinib
Mavyret (glecaprevir/ pibrentasvir)

+

gilteritinib

2 interactions

Monitor/Modify Tx

glecaprevir + gilteritinib

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport possibly inhibited)

pibrentasvir + gilteritinib

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport possibly inhibited)

• glyburide
Mavyret (glecaprevir/ pibrentasvir)

+

glyburide

2 interactions

Monitor/Modify Tx

glecaprevir + glyburide

monitor glucose: combo may incr. glyburide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

pibrentasvir + glyburide

monitor glucose: combo may incr. glyburide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• ibrutinib
Mavyret (glecaprevir/ pibrentasvir)

+

ibrutinib

2 interactions

Monitor/Modify Tx

glecaprevir + ibrutinib

consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; gut P-gp-mediated transport inhibited, BCRP-mediated transport possibly inhibited)

pibrentasvir + ibrutinib

consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; gut P-gp-mediated transport inhibited, BCRP-mediated transport possibly inhibited)

• idelalisib
Mavyret (glecaprevir/ pibrentasvir)

+

idelalisib

2 interactions

Monitor/Modify Tx

glecaprevir + idelalisib

monitor LFTs, CBC, GI toxicity sx: combo may incr. idelalisib levels, risk of hepatotoxicity, serious infection, myelosuppression, GI toxicity, pneumonitis, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + idelalisib

monitor LFTs, CBC, GI toxicity sx: combo may incr. idelalisib levels, risk of hepatotoxicity, serious infection, myelosuppression, GI toxicity, pneumonitis, other adverse effects (P-gp-mediated transport inhibited)

• imatinib
Mavyret (glecaprevir/ pibrentasvir)

+

imatinib

2 interactions

Monitor/Modify Tx

glecaprevir + imatinib

monitor CBC: combo may incr. levels of both drugs, risk of myelosuppression, other adverse effects (BCRP-mediated transport inhibited)

pibrentasvir + imatinib

monitor CBC: combo may incr. levels of both drugs, risk of myelosuppression, other adverse effects (BCRP-mediated transport inhibited)

• infigratinib
Mavyret (glecaprevir/ pibrentasvir)

+

infigratinib

2 interactions

Monitor/Modify Tx

glecaprevir + infigratinib

monitor phosphate: combo may incr. infigratinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + infigratinib

monitor phosphate: combo may incr. infigratinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• irinotecan
Mavyret (glecaprevir/ pibrentasvir)

+

irinotecan

2 interactions

Monitor/Modify Tx

glecaprevir + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (BCRP-mediated transport inhibited)

pibrentasvir + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (BCRP-mediated transport inhibited)

• ivabradine
Mavyret (glecaprevir/ pibrentasvir)

+

ivabradine

2 interactions

Monitor/Modify Tx

glecaprevir + ivabradine

monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + ivabradine

monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ixabepilone
Mavyret (glecaprevir/ pibrentasvir)

+

ixabepilone

2 interactions

Monitor/Modify Tx

glecaprevir + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• lapatinib
Mavyret (glecaprevir/ pibrentasvir)

+

lapatinib

2 interactions

Monitor/Modify Tx

glecaprevir + lapatinib

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + lapatinib

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• lemborexant
Mavyret (glecaprevir/ pibrentasvir)

+

lemborexant

2 interactions

Monitor/Modify Tx

glecaprevir + lemborexant

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

pibrentasvir + lemborexant

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• levoketoconazole
Mavyret (glecaprevir/ pibrentasvir)

+

levoketoconazole

2 interactions

Monitor/Modify Tx

glecaprevir + levoketoconazole

consider monitoring ECG: combo may incr. levoketoconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + levoketoconazole

consider monitoring ECG: combo may incr. levoketoconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• lomitapide
Mavyret (glecaprevir/ pibrentasvir)

+

lomitapide

2 interactions

Monitor/Modify Tx

glecaprevir + lomitapide

adjust max lomitapide dose to 30 mg/day: combo may incr. levels of both drugs, risk of adverse effects (hepatic metab. inhibited, gut P-gp-mediated transport possibly inhibited)

pibrentasvir + lomitapide

adjust max lomitapide dose to 30 mg/day: combo may incr. levels of both drugs, risk of adverse effects (hepatic metab. inhibited, gut P-gp-mediated transport possibly inhibited)

• lonafarnib
Mavyret (glecaprevir/ pibrentasvir)

+

lonafarnib

2 interactions

Monitor/Modify Tx

glecaprevir + lonafarnib

consider monitoring HR, ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + lonafarnib

consider monitoring HR, ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• loperamide
Mavyret (glecaprevir/ pibrentasvir)

+

loperamide

2 interactions

Monitor/Modify Tx

glecaprevir + loperamide

monitor ECG, esp. if also combined w/ CYP2C8, CYP3A4 inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + loperamide

monitor ECG, esp. if also combined w/ CYP2C8, CYP3A4 inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• lumateperone
Mavyret (glecaprevir/ pibrentasvir)

+

lumateperone

2 interactions

Monitor/Modify Tx

glecaprevir + lumateperone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + lumateperone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lurasidone
Mavyret (glecaprevir/ pibrentasvir)

+

lurasidone

2 interactions

Monitor/Modify Tx

glecaprevir + lurasidone

monitor ECG: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + lurasidone

monitor ECG: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lurbinectedin
Mavyret (glecaprevir/ pibrentasvir)

+

lurbinectedin

2 interactions

Monitor/Modify Tx

glecaprevir + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

pibrentasvir + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• mavorixafor
Mavyret (glecaprevir/ pibrentasvir)

+

mavorixafor

2 interactions

Monitor/Modify Tx

glecaprevir + mavorixafor

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + mavorixafor

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• methotrexate
Mavyret (glecaprevir/ pibrentasvir)

+

methotrexate

2 interactions

Monitor/Modify Tx

glecaprevir + methotrexate

monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport inhibited)

pibrentasvir + methotrexate

monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport inhibited)

• midazolam
Mavyret (glecaprevir/ pibrentasvir)

+

midazolam

2 interactions

Monitor/Modify Tx

glecaprevir + midazolam

monitor resp. rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

pibrentasvir + midazolam

monitor resp. rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• mitoxantrone
Mavyret (glecaprevir/ pibrentasvir)

+

mitoxantrone

2 interactions

Monitor/Modify Tx

glecaprevir + mitoxantrone

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + mitoxantrone

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• mobocertinib
Mavyret (glecaprevir/ pibrentasvir)

+

mobocertinib

2 interactions

Monitor/Modify Tx

glecaprevir + mobocertinib

monitor ECG: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

pibrentasvir + mobocertinib

monitor ECG: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• momelotinib
Mavyret (glecaprevir/ pibrentasvir)

+

momelotinib

2 interactions

Monitor/Modify Tx

glecaprevir + momelotinib

monitor CBC, bleeding s/sx: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + momelotinib

monitor CBC, bleeding s/sx: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• morphine
Mavyret (glecaprevir/ pibrentasvir)

+

morphine

2 interactions

Monitor/Modify Tx

glecaprevir + morphine

monitor resp. rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + morphine

monitor resp. rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• nateglinide
Mavyret (glecaprevir/ pibrentasvir)

+

nateglinide

2 interactions

Monitor/Modify Tx

glecaprevir + nateglinide

monitor glucose: combo may incr. nateglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

pibrentasvir + nateglinide

monitor glucose: combo may incr. nateglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• nifedipine
Mavyret (glecaprevir/ pibrentasvir)

+

nifedipine

2 interactions

Monitor/Modify Tx

glecaprevir + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• nimodipine
Mavyret (glecaprevir/ pibrentasvir)

+

nimodipine

2 interactions

Monitor/Modify Tx

glecaprevir + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

pibrentasvir + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nintedanib
Mavyret (glecaprevir/ pibrentasvir)

+

nintedanib

2 interactions

Monitor/Modify Tx

glecaprevir + nintedanib

consider decr. nintedanib dose: combo may incr. nintedanib levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + nintedanib

consider decr. nintedanib dose: combo may incr. nintedanib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• nisoldipine
Mavyret (glecaprevir/ pibrentasvir)

+

nisoldipine

2 interactions

Monitor/Modify Tx

glecaprevir + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

pibrentasvir + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• oliceridine
Mavyret (glecaprevir/ pibrentasvir)

+

oliceridine

2 interactions

Monitor/Modify Tx

glecaprevir + oliceridine

monitor resp. rate, ECG: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

pibrentasvir + oliceridine

monitor resp. rate, ECG: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• paclitaxel
Mavyret (glecaprevir/ pibrentasvir)

+

paclitaxel

2 interactions

Monitor/Modify Tx

glecaprevir + paclitaxel

monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + paclitaxel

monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

• pemigatinib
Mavyret (glecaprevir/ pibrentasvir)

+

pemigatinib

2 interactions

Monitor/Modify Tx

glecaprevir + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• pitavastatin
Mavyret (glecaprevir/ pibrentasvir)

+

pitavastatin

2 interactions

Monitor/Modify Tx

glecaprevir + pitavastatin

monitor CK, myopathy sx; use lowest effective pitavastatin dose: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + pitavastatin

monitor CK, myopathy sx; use lowest effective pitavastatin dose: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• posaconazole
Mavyret (glecaprevir/ pibrentasvir)

+

posaconazole

2 interactions

Monitor/Modify Tx

glecaprevir + posaconazole

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + posaconazole

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• pravastatin
Mavyret (glecaprevir/ pibrentasvir)

+

pravastatin

2 interactions

Monitor/Modify Tx

glecaprevir + pravastatin

decr. pravastatin dose 50%; monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited, hepatic transport inhibited)

pibrentasvir + pravastatin

decr. pravastatin dose 50%; monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited, hepatic transport inhibited)

• quinidine (antiarrhythmic)
Mavyret (glecaprevir/ pibrentasvir)

+

quinidine (antiarrhythmic)

2 interactions

Monitor/Modify Tx

glecaprevir + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• quinidine (CYP2D6 inhibitor)
Mavyret (glecaprevir/ pibrentasvir)

+

quinidine (CYP2D6 inhibitor)

2 interactions

Monitor/Modify Tx

glecaprevir + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• quinine
Mavyret (glecaprevir/ pibrentasvir)

+

quinine

2 interactions

Monitor/Modify Tx

glecaprevir + quinine

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + quinine

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• ranolazine
Mavyret (glecaprevir/ pibrentasvir)

+

ranolazine

2 interactions

Monitor/Modify Tx

glecaprevir + ranolazine

monitor ECG; consider decr. ranolazine dose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + ranolazine

monitor ECG; consider decr. ranolazine dose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• red yeast rice
Mavyret (glecaprevir/ pibrentasvir)

+

red yeast rice

2 interactions

Monitor/Modify Tx

glecaprevir + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, hepatic transport inhibited, red yeast rice contains varying amounts of lovastatin)

pibrentasvir + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, hepatic transport inhibited, red yeast rice contains varying amounts of lovastatin)

• repaglinide
Mavyret (glecaprevir/ pibrentasvir)

+

repaglinide

2 interactions

Monitor/Modify Tx

glecaprevir + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

pibrentasvir + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• ribociclib
Mavyret (glecaprevir/ pibrentasvir)

+

ribociclib

2 interactions

Monitor/Modify Tx

glecaprevir + ribociclib

monitor ECG, electrolytes, CBC: combo may incr. ribociclib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

pibrentasvir + ribociclib

monitor ECG, electrolytes, CBC: combo may incr. ribociclib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• rimegepant
Mavyret (glecaprevir/ pibrentasvir)

+

rimegepant

2 interactions

Monitor/Modify Tx

glecaprevir + rimegepant

separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + rimegepant

separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (P-gp-mediated transport inhibited)

• riociguat
Mavyret (glecaprevir/ pibrentasvir)

+

riociguat

2 interactions

Monitor/Modify Tx

glecaprevir + riociguat

consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + riociguat

consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• romidepsin
Mavyret (glecaprevir/ pibrentasvir)

+

romidepsin

2 interactions

Monitor/Modify Tx

glecaprevir + romidepsin

monitor ECG, CBC: combo may incr. romidepsin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + romidepsin

monitor ECG, CBC: combo may incr. romidepsin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

• rosuvastatin
Mavyret (glecaprevir/ pibrentasvir)

+

rosuvastatin

2 interactions

Monitor/Modify Tx

glecaprevir + rosuvastatin

decr. rosuvastatin start dose to 5 mg qd; adjust max rosuvastatin dose to 10 mg qd; monitor CK, myopathy sx: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + rosuvastatin

decr. rosuvastatin start dose to 5 mg qd; adjust max rosuvastatin dose to 10 mg qd; monitor CK, myopathy sx: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• selpercatinib
Mavyret (glecaprevir/ pibrentasvir)

+

selpercatinib

2 interactions

Monitor/Modify Tx

glecaprevir + selpercatinib

monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + selpercatinib

monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• selumetinib
Mavyret (glecaprevir/ pibrentasvir)

+

selumetinib

2 interactions

Monitor/Modify Tx

glecaprevir + selumetinib

monitor LVEF, CK, myopathy sx: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

pibrentasvir + selumetinib

monitor LVEF, CK, myopathy sx: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• sufentanil
Mavyret (glecaprevir/ pibrentasvir)

+

sufentanil

2 interactions

Monitor/Modify Tx

glecaprevir + sufentanil

monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

pibrentasvir + sufentanil

monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• tacrolimus
Mavyret (glecaprevir/ pibrentasvir)

+

tacrolimus

2 interactions

Monitor/Modify Tx

glecaprevir + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• tadalafil
Mavyret (glecaprevir/ pibrentasvir)

+

tadalafil

2 interactions

Monitor/Modify Tx

glecaprevir + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

pibrentasvir + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• talazoparib
Mavyret (glecaprevir/ pibrentasvir)

+

talazoparib

2 interactions

Monitor/Modify Tx

glecaprevir + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• temsirolimus
Mavyret (glecaprevir/ pibrentasvir)

+

temsirolimus

2 interactions

Monitor/Modify Tx

glecaprevir + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport possibly inhibited)

• theophylline
Mavyret (glecaprevir/ pibrentasvir)

+

theophylline

2 interactions

Monitor/Modify Tx

glecaprevir + theophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metab. inhibited)

pibrentasvir + theophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metab. inhibited)

• tolvaptan
Mavyret (glecaprevir/ pibrentasvir)

+

tolvaptan

2 interactions

Monitor/Modify Tx

glecaprevir + tolvaptan

consider decr. tolvaptan dose: combo may incr. levels of both drugs, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + tolvaptan

consider decr. tolvaptan dose: combo may incr. levels of both drugs, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• triazolam
Mavyret (glecaprevir/ pibrentasvir)

+

triazolam

2 interactions

Monitor/Modify Tx

glecaprevir + triazolam

monitor resp. rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

pibrentasvir + triazolam

monitor resp. rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ubrogepant
Mavyret (glecaprevir/ pibrentasvir)

+

ubrogepant

2 interactions

Monitor/Modify Tx

glecaprevir + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• vardenafil
Mavyret (glecaprevir/ pibrentasvir)

+

vardenafil

2 interactions

Monitor/Modify Tx

glecaprevir + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited)

pibrentasvir + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• vimseltinib
Mavyret (glecaprevir/ pibrentasvir)

+

vimseltinib

2 interactions

Monitor/Modify Tx

glecaprevir + vimseltinib

give vimseltinib at least 4h before glecaprevir: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport possibly inhibited)

pibrentasvir + vimseltinib

give vimseltinib at least 4h before pibrentasvir: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport possibly inhibited)

• vinblastine
Mavyret (glecaprevir/ pibrentasvir)

+

vinblastine

2 interactions

Monitor/Modify Tx

glecaprevir + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

pibrentasvir + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• vincristine
Mavyret (glecaprevir/ pibrentasvir)

+

vincristine

2 interactions

Monitor/Modify Tx

glecaprevir + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• vinorelbine
Mavyret (glecaprevir/ pibrentasvir)

+

vinorelbine

2 interactions

Monitor/Modify Tx

glecaprevir + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• warfarin
Mavyret (glecaprevir/ pibrentasvir)

+

warfarin

2 interactions

Monitor/Modify Tx

glecaprevir + warfarin

monitor INR, bleeding s/sx: combo may incr. or decr. warfarin levels, incr. risk of bleeding (incl. life-threatening), other adverse effects or decr. efficacy (hepatic metab. inhibited; mechanism unknown, viral eradication may improve hepatic metabolic function)

pibrentasvir + warfarin

monitor INR, bleeding s/sx: combo may incr. or decr. warfarin levels, incr. risk of bleeding (incl. life-threatening), other adverse effects or decr. efficacy (hepatic metab. inhibited; mechanism unknown, viral eradication may improve hepatic metabolic function)

• zanubrutinib
Mavyret (glecaprevir/ pibrentasvir)

+

zanubrutinib

2 interactions

Monitor/Modify Tx

glecaprevir + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

pibrentasvir + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

Caution Advised

• abrocitinib
Mavyret (glecaprevir/ pibrentasvir)

+

abrocitinib

2 interactions

Caution Advised

glecaprevir + abrocitinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + abrocitinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• adagrasib
Mavyret (glecaprevir/ pibrentasvir)

+

adagrasib

2 interactions

Caution Advised

glecaprevir + adagrasib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + adagrasib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• aliskiren
Mavyret (glecaprevir/ pibrentasvir)

+

aliskiren

2 interactions

Caution Advised

glecaprevir + aliskiren

caution advised: combo may incr. aliskiren levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + aliskiren

caution advised: combo may incr. aliskiren levels, risk of adverse effects (P-gp-mediated transport inhibited)

• alosetron
Mavyret (glecaprevir/ pibrentasvir)

+

alosetron

2 interactions

Caution Advised

glecaprevir + alosetron

caution advised: combo may incr. alosetron levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + alosetron

caution advised: combo may incr. alosetron levels, risk of adverse effects (hepatic metab. inhibited)

• armodafinil
Mavyret (glecaprevir/ pibrentasvir)

+

armodafinil

1 interaction

Caution Advised

glecaprevir + armodafinil

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• artemether/lumefantrine
Mavyret (glecaprevir/ pibrentasvir)

+

artemether/ lumefantrine

1 interaction

Caution Advised

glecaprevir + artemether/ lumefantrine

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• asciminib
Mavyret (glecaprevir/ pibrentasvir)

+

asciminib

2 interactions

Caution Advised

glecaprevir + asciminib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited, hepatic transport possibly inhibited)

pibrentasvir + asciminib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited)

• azithromycin
Mavyret (glecaprevir/ pibrentasvir)

+

azithromycin

2 interactions

Caution Advised

glecaprevir + azithromycin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + azithromycin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• belumosudil
Mavyret (glecaprevir/ pibrentasvir)

+

belumosudil

2 interactions

Caution Advised

glecaprevir + belumosudil

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + belumosudil

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• belzutifan
Mavyret (glecaprevir/ pibrentasvir)

+

belzutifan

1 interaction

Caution Advised

glecaprevir + belzutifan

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• bempedoic acid
Mavyret (glecaprevir/ pibrentasvir)

+

bempedoic acid

1 interaction

Caution Advised

glecaprevir + bempedoic acid

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited)

• berotralstat
Mavyret (glecaprevir/ pibrentasvir)

+

berotralstat

2 interactions

Caution Advised

glecaprevir + berotralstat

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + berotralstat

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• bexarotene
Mavyret (glecaprevir/ pibrentasvir)

+

bexarotene

1 interaction

Caution Advised

glecaprevir + bexarotene

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• bisoprolol
Mavyret (glecaprevir/ pibrentasvir)

+

bisoprolol

2 interactions

Caution Advised

glecaprevir + bisoprolol

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + bisoprolol

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• canagliflozin
Mavyret (glecaprevir/ pibrentasvir)

+

canagliflozin

2 interactions

Caution Advised

glecaprevir + canagliflozin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + canagliflozin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• cannabidiol
Mavyret (glecaprevir/ pibrentasvir)

+

cannabidiol

2 interactions

Caution Advised

glecaprevir + cannabidiol

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

pibrentasvir + cannabidiol

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• capmatinib
Mavyret (glecaprevir/ pibrentasvir)

+

capmatinib

2 interactions

Caution Advised

glecaprevir + capmatinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + capmatinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• captopril
Mavyret (glecaprevir/ pibrentasvir)

+

captopril

2 interactions

Caution Advised

glecaprevir + captopril

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + captopril

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• cariprazine
Mavyret (glecaprevir/ pibrentasvir)

+

cariprazine

2 interactions

Caution Advised

glecaprevir + cariprazine

caution advised: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + cariprazine

caution advised: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

• ceftobiprole
Mavyret (glecaprevir/ pibrentasvir)

+

ceftobiprole

1 interaction

Caution Advised

glecaprevir + ceftobiprole

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport possibly inhibited)

• cimetidine
Mavyret (glecaprevir/ pibrentasvir)

+

cimetidine

2 interactions

Caution Advised

glecaprevir + cimetidine

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + cimetidine

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• clarithromycin
Mavyret (glecaprevir/ pibrentasvir)

+

clarithromycin

2 interactions

Caution Advised

glecaprevir + clarithromycin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, hepatic transport inhibited)

pibrentasvir + clarithromycin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• clobazam
Mavyret (glecaprevir/ pibrentasvir)

+

clobazam

1 interaction

Caution Advised

glecaprevir + clobazam

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• clopidogrel
Mavyret (glecaprevir/ pibrentasvir)

+

clopidogrel

1 interaction

Caution Advised

glecaprevir + clopidogrel

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited)

• cobicistat
Mavyret (glecaprevir/ pibrentasvir)

+

cobicistat

2 interactions

Caution Advised

glecaprevir + cobicistat

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + cobicistat

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• cobimetinib
Mavyret (glecaprevir/ pibrentasvir)

+

cobimetinib

2 interactions

Caution Advised

glecaprevir + cobimetinib

caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + cobimetinib

caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metab. inhibited)

• conivaptan
Mavyret (glecaprevir/ pibrentasvir)

+

conivaptan

2 interactions

Caution Advised

glecaprevir + conivaptan

caution advised: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + conivaptan

caution advised: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• cyclophosphamide
Mavyret (glecaprevir/ pibrentasvir)

+

cyclophosphamide

2 interactions

Caution Advised

glecaprevir + cyclophosphamide

caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy (hepatic metab. possibly inhibited, decr. conversion to active metabolite)

pibrentasvir + cyclophosphamide

caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy (hepatic metab. possibly inhibited, decr. conversion to active metabolite)

• danicopan
Mavyret (glecaprevir/ pibrentasvir)

+

danicopan

2 interactions

Caution Advised

glecaprevir + danicopan

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + danicopan

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• danshen
Mavyret (glecaprevir/ pibrentasvir)

+

danshen

2 interactions

Caution Advised

glecaprevir + danshen

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

pibrentasvir + danshen

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport induced)

• daridorexant
Mavyret (glecaprevir/ pibrentasvir)

+

daridorexant

2 interactions

Caution Advised

glecaprevir + daridorexant

caution advised: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

pibrentasvir + daridorexant

caution advised: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• darolutamide
Mavyret (glecaprevir/ pibrentasvir)

+

darolutamide

2 interactions

Caution Advised

glecaprevir + darolutamide

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited; BCRP-mediated transport inhibited, hepatic transport inhibited; hepatic metab. induced)

pibrentasvir + darolutamide

caution advised: combo may incr. levels of both drugs, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• deflazacort
Mavyret (glecaprevir/ pibrentasvir)

+

deflazacort

2 interactions

Caution Advised

glecaprevir + deflazacort

caution advised: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression (P-gp-mediated transport inhibited)

pibrentasvir + deflazacort

caution advised: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression (P-gp-mediated transport inhibited)

• dexamethasone
Mavyret (glecaprevir/ pibrentasvir)

+

dexamethasone

1 interaction

Caution Advised

glecaprevir + dexamethasone

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• dicloxacillin
Mavyret (glecaprevir/ pibrentasvir)

+

dicloxacillin

2 interactions

Caution Advised

glecaprevir + dicloxacillin

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

pibrentasvir + dicloxacillin

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport induced)

• dihydroergotamine
Mavyret (glecaprevir/ pibrentasvir)

+

dihydroergotamine

2 interactions

Caution Advised

glecaprevir + dihydroergotamine

caution advised: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + dihydroergotamine

caution advised: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• diosmin
Mavyret (glecaprevir/ pibrentasvir)

+

diosmin

2 interactions

Caution Advised

glecaprevir + diosmin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + diosmin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• dronedarone
Mavyret (glecaprevir/ pibrentasvir)

+

dronedarone

2 interactions

Caution Advised

glecaprevir + dronedarone

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + dronedarone

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• echinacea
Mavyret (glecaprevir/ pibrentasvir)

+

echinacea

1 interaction

Caution Advised

glecaprevir + echinacea

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• elacestrant
Mavyret (glecaprevir/ pibrentasvir)

+

elacestrant

2 interactions

Caution Advised

glecaprevir + elacestrant

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + elacestrant

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• elafibranor
Mavyret (glecaprevir/ pibrentasvir)

+

elafibranor

1 interaction

Caution Advised

glecaprevir + elafibranor

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• elbasvir
Mavyret (glecaprevir/ pibrentasvir)

+

elbasvir

2 interactions

Caution Advised

glecaprevir + elbasvir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (gut BCRP-mediated transport inhibited)

pibrentasvir + elbasvir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (gut BCRP-mediated transport inhibited)

• elexacaftor/tezacaftor/ivacaftor
Mavyret (glecaprevir/ pibrentasvir)

+

elexacaftor/ tezacaftor/ ivacaftor

2 interactions

Caution Advised

glecaprevir + elexacaftor/ tezacaftor/ ivacaftor

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport possibly inhibited, P-gp-mediated transport inhibited)

pibrentasvir + elexacaftor/ tezacaftor/ ivacaftor

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• eltrombopag
Mavyret (glecaprevir/ pibrentasvir)

+

eltrombopag

2 interactions

Caution Advised

glecaprevir + eltrombopag

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + eltrombopag

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• enasidenib
Mavyret (glecaprevir/ pibrentasvir)

+

enasidenib

2 interactions

Caution Advised

glecaprevir + enasidenib

caution advised: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited, hepatic transport inhibited, hepatic metab. induced)

pibrentasvir + enasidenib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• eplerenone
Mavyret (glecaprevir/ pibrentasvir)

+

eplerenone

2 interactions

Caution Advised

glecaprevir + eplerenone

caution advised: combo may incr. eplerenone levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + eplerenone

caution advised: combo may incr. eplerenone levels, risk of adverse effects (hepatic metab. inhibited)

• ergotamine
Mavyret (glecaprevir/ pibrentasvir)

+

ergotamine

2 interactions

Caution Advised

glecaprevir + ergotamine

caution advised: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + ergotamine

caution advised: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• eslicarbazepine acetate
Mavyret (glecaprevir/ pibrentasvir)

+

eslicarbazepine acetate

1 interaction

Caution Advised

glecaprevir + eslicarbazepine acetate

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• febuxostat
Mavyret (glecaprevir/ pibrentasvir)

+

febuxostat

2 interactions

Caution Advised

glecaprevir + febuxostat

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited)

pibrentasvir + febuxostat

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• felbamate
Mavyret (glecaprevir/ pibrentasvir)

+

felbamate

1 interaction

Caution Advised

glecaprevir + felbamate

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• fluvoxamine
Mavyret (glecaprevir/ pibrentasvir)

+

fluvoxamine

2 interactions

Caution Advised

glecaprevir + fluvoxamine

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + fluvoxamine

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• fosamprenavir
Mavyret (glecaprevir/ pibrentasvir)

+

fosamprenavir

1 interaction

Caution Advised

glecaprevir + fosamprenavir

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• fostamatinib
Mavyret (glecaprevir/ pibrentasvir)

+

fostamatinib

2 interactions

Caution Advised

glecaprevir + fostamatinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + fostamatinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• fostemsavir
Mavyret (glecaprevir/ pibrentasvir)

+

fostemsavir

2 interactions

Caution Advised

glecaprevir + fostemsavir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + fostemsavir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• garlic
Mavyret (glecaprevir/ pibrentasvir)

+

garlic

1 interaction

Caution Advised

glecaprevir + garlic

caution advised w/ supplemental garlic; dietary intake OK: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• gemfibrozil
Mavyret (glecaprevir/ pibrentasvir)

+

gemfibrozil

1 interaction

Caution Advised

glecaprevir + gemfibrozil

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited)

• ginkgo
Mavyret (glecaprevir/ pibrentasvir)

+

ginkgo

2 interactions

Caution Advised

glecaprevir + ginkgo

caution advised: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

pibrentasvir + ginkgo

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• ginseng, Asian
Mavyret (glecaprevir/ pibrentasvir)

+

ginseng, Asian

1 interaction

Caution Advised

glecaprevir + ginseng, Asian

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• glycerol phenylbutyrate
Mavyret (glecaprevir/ pibrentasvir)

+

glycerol phenylbutyrate

1 interaction

Caution Advised

glecaprevir + glycerol phenylbutyrate

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• griseofulvin
Mavyret (glecaprevir/ pibrentasvir)

+

griseofulvin

1 interaction

Caution Advised

glecaprevir + griseofulvin

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• indomethacin
Mavyret (glecaprevir/ pibrentasvir)

+

indomethacin

2 interactions

Caution Advised

glecaprevir + indomethacin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + indomethacin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• irbesartan
Mavyret (glecaprevir/ pibrentasvir)

+

irbesartan

1 interaction

Caution Advised

glecaprevir + irbesartan

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited)

• isavuconazonium
Mavyret (glecaprevir/ pibrentasvir)

+

isavuconazonium

2 interactions

Caution Advised

glecaprevir + isavuconazonium

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + isavuconazonium

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• istradefylline
Mavyret (glecaprevir/ pibrentasvir)

+

istradefylline

2 interactions

Caution Advised

glecaprevir + istradefylline

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + istradefylline

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• itraconazole
Mavyret (glecaprevir/ pibrentasvir)

+

itraconazole

2 interactions

Caution Advised

glecaprevir + itraconazole

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + itraconazole

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• ivacaftor
Mavyret (glecaprevir/ pibrentasvir)

+

ivacaftor

2 interactions

Caution Advised

glecaprevir + ivacaftor

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + ivacaftor

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• ketoconazole
Mavyret (glecaprevir/ pibrentasvir)

+

ketoconazole

2 interactions

Caution Advised

glecaprevir + ketoconazole

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + ketoconazole

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• larotrectinib
Mavyret (glecaprevir/ pibrentasvir)

+

larotrectinib

2 interactions

Caution Advised

glecaprevir + larotrectinib

caution advised: combo may incr. larotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + larotrectinib

caution advised: combo may incr. larotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• lasmiditan
Mavyret (glecaprevir/ pibrentasvir)

+

lasmiditan

2 interactions

Caution Advised

glecaprevir + lasmiditan

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + lasmiditan

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• lazertinib
Mavyret (glecaprevir/ pibrentasvir)

+

lazertinib

2 interactions

Caution Advised

glecaprevir + lazertinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited)

pibrentasvir + lazertinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• ledipasvir
Mavyret (glecaprevir/ pibrentasvir)

+

ledipasvir

2 interactions

Caution Advised

glecaprevir + ledipasvir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport possibly inhibited)

pibrentasvir + ledipasvir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport possibly inhibited)

• leflunomide
Mavyret (glecaprevir/ pibrentasvir)

+

leflunomide

2 interactions

Caution Advised

glecaprevir + leflunomide

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + leflunomide

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• leniolisib
Mavyret (glecaprevir/ pibrentasvir)

+

leniolisib

2 interactions

Caution Advised

glecaprevir + leniolisib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport possibly inhibited, hepatic transport possibly inhibited)

pibrentasvir + leniolisib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

• letermovir
Mavyret (glecaprevir/ pibrentasvir)

+

letermovir

1 interaction

Caution Advised

glecaprevir + letermovir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited)

• levacetylleucine
Mavyret (glecaprevir/ pibrentasvir)

+

levacetylleucine

2 interactions

Caution Advised

glecaprevir + levacetylleucine

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

pibrentasvir + levacetylleucine

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• maraviroc
Mavyret (glecaprevir/ pibrentasvir)

+

maraviroc

2 interactions

Caution Advised

glecaprevir + maraviroc

caution advised: combo may incr. maraviroc levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + maraviroc

caution advised: combo may incr. maraviroc levels, risk of adverse effects (P-gp-mediated transport inhibited)

• maribavir
Mavyret (glecaprevir/ pibrentasvir)

+

maribavir

2 interactions

Caution Advised

glecaprevir + maribavir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + maribavir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• meropenem
Mavyret (glecaprevir/ pibrentasvir)

+

meropenem

2 interactions

Caution Advised

glecaprevir + meropenem

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. possibly induced, P-gp-mediated transport possibly induced)

pibrentasvir + meropenem

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport possibly induced)

• methylergonovine
Mavyret (glecaprevir/ pibrentasvir)

+

methylergonovine

2 interactions

Caution Advised

glecaprevir + methylergonovine

caution advised: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

pibrentasvir + methylergonovine

caution advised: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• midostaurin
Mavyret (glecaprevir/ pibrentasvir)

+

midostaurin

2 interactions

Caution Advised

glecaprevir + midostaurin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + midostaurin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• mifepristone
Mavyret (glecaprevir/ pibrentasvir)

+

mifepristone

2 interactions

Caution Advised

glecaprevir + mifepristone

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + mifepristone

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• milk thistle
Mavyret (glecaprevir/ pibrentasvir)

+

milk thistle

2 interactions

Caution Advised

glecaprevir + milk thistle

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + milk thistle

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• mirabegron
Mavyret (glecaprevir/ pibrentasvir)

+

mirabegron

2 interactions

Caution Advised

glecaprevir + mirabegron

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + mirabegron

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• naldemedine
Mavyret (glecaprevir/ pibrentasvir)

+

naldemedine

2 interactions

Caution Advised

glecaprevir + naldemedine

caution advised: combo may incr. naldemedine levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + naldemedine

caution advised: combo may incr. naldemedine levels, risk of adverse effects (P-gp-mediated transport inhibited)

• naproxen
Mavyret (glecaprevir/ pibrentasvir)

+

naproxen

2 interactions

Caution Advised

glecaprevir + naproxen

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + naproxen

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• nefazodone
Mavyret (glecaprevir/ pibrentasvir)

+

nefazodone

2 interactions

Caution Advised

glecaprevir + nefazodone

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + nefazodone

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• nelfinavir
Mavyret (glecaprevir/ pibrentasvir)

+

nelfinavir

2 interactions

Caution Advised

glecaprevir + nelfinavir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + nelfinavir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• odevixibat
Mavyret (glecaprevir/ pibrentasvir)

+

odevixibat

1 interaction

Caution Advised

glecaprevir + odevixibat

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• olutasidenib
Mavyret (glecaprevir/ pibrentasvir)

+

olutasidenib

1 interaction

Caution Advised

glecaprevir + olutasidenib

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. possibly induced)

• omaveloxolone
Mavyret (glecaprevir/ pibrentasvir)

+

omaveloxolone

2 interactions

Caution Advised

glecaprevir + omaveloxolone

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, hepatic transport induced, BCRP-mediated transport induced)

pibrentasvir + omaveloxolone

caution advised: combo may decr. pibrentasvir levels, efficacy (BCRP-mediated transport induced)

• osimertinib
Mavyret (glecaprevir/ pibrentasvir)

+

osimertinib

2 interactions

Caution Advised

glecaprevir + osimertinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + osimertinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• oteseconazole
Mavyret (glecaprevir/ pibrentasvir)

+

oteseconazole

2 interactions

Caution Advised

glecaprevir + oteseconazole

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited)

pibrentasvir + oteseconazole

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• oxcarbazepine
Mavyret (glecaprevir/ pibrentasvir)

+

oxcarbazepine

2 interactions

Caution Advised

glecaprevir + oxcarbazepine

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly induced)

pibrentasvir + oxcarbazepine

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport possibly induced)

• palovarotene
Mavyret (glecaprevir/ pibrentasvir)

+

palovarotene

2 interactions

Caution Advised

glecaprevir + palovarotene

caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + palovarotene

caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metab. inhibited)

• paroxetine
Mavyret (glecaprevir/ pibrentasvir)

+

paroxetine

2 interactions

Caution Advised

glecaprevir + paroxetine

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + paroxetine

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• perampanel
Mavyret (glecaprevir/ pibrentasvir)

+

perampanel

1 interaction

Caution Advised

glecaprevir + perampanel

caution advised if on perampanel 12 mg/day: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• pioglitazone
Mavyret (glecaprevir/ pibrentasvir)

+

pioglitazone

1 interaction

Caution Advised

glecaprevir + pioglitazone

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• pirfenidone
Mavyret (glecaprevir/ pibrentasvir)

+

pirfenidone

2 interactions

Caution Advised

glecaprevir + pirfenidone

caution advised: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + pirfenidone

caution advised: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metab. inhibited)

• pirtobrutinib
Mavyret (glecaprevir/ pibrentasvir)

+

pirtobrutinib

2 interactions

Caution Advised

glecaprevir + pirtobrutinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + pirtobrutinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• ponatinib
Mavyret (glecaprevir/ pibrentasvir)

+

ponatinib

2 interactions

Caution Advised

glecaprevir + ponatinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

pibrentasvir + ponatinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• prednisone
Mavyret (glecaprevir/ pibrentasvir)

+

prednisone

1 interaction

Caution Advised

glecaprevir + prednisone

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• pretomanid
Mavyret (glecaprevir/ pibrentasvir)

+

pretomanid

2 interactions

Caution Advised

glecaprevir + pretomanid

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport possibly inhibited, BCRP-mediated transport possibly inhibited, P-gp-mediated transport possibly inhibited)

pibrentasvir + pretomanid

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport possibly inhibited, P-gp-mediated transport possibly inhibited)

• quercetin
Mavyret (glecaprevir/ pibrentasvir)

+

quercetin

2 interactions

Caution Advised

glecaprevir + quercetin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + quercetin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• regorafenib
Mavyret (glecaprevir/ pibrentasvir)

+

regorafenib

2 interactions

Caution Advised

glecaprevir + regorafenib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited)

pibrentasvir + regorafenib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• rifaximin
Mavyret (glecaprevir/ pibrentasvir)

+

rifaximin

2 interactions

Caution Advised

glecaprevir + rifaximin

caution advised: combo may incr. rifaximin levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + rifaximin

caution advised: combo may incr. rifaximin levels, risk of adverse effects (P-gp-mediated transport inhibited)

• roflumilast
Mavyret (glecaprevir/ pibrentasvir)

+

roflumilast

2 interactions

Caution Advised

glecaprevir + roflumilast

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + roflumilast

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

• roflumilast topical
Mavyret (glecaprevir/ pibrentasvir)

+

roflumilast topical

2 interactions

Caution Advised

glecaprevir + roflumilast topical

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + roflumilast topical

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

• rolapitant
Mavyret (glecaprevir/ pibrentasvir)

+

rolapitant

2 interactions

Caution Advised

glecaprevir + rolapitant

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + rolapitant

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• rucaparib
Mavyret (glecaprevir/ pibrentasvir)

+

rucaparib

2 interactions

Caution Advised

glecaprevir + rucaparib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + rucaparib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• rufinamide
Mavyret (glecaprevir/ pibrentasvir)

+

rufinamide

1 interaction

Caution Advised

glecaprevir + rufinamide

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• sacubitril
Mavyret (glecaprevir/ pibrentasvir)

+

sacubitril

1 interaction

Caution Advised

glecaprevir + sacubitril

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited)

• sarecycline
Mavyret (glecaprevir/ pibrentasvir)

+

sarecycline

2 interactions

Caution Advised

glecaprevir + sarecycline

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + sarecycline

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• sarilumab
Mavyret (glecaprevir/ pibrentasvir)

+

sarilumab

1 interaction

Caution Advised

glecaprevir + sarilumab

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

• seladelpar
Mavyret (glecaprevir/ pibrentasvir)

+

seladelpar

2 interactions

Caution Advised

glecaprevir + seladelpar

caution advised: combo may incr. seladelpar levels, risk of adverse effects (BCRP-mediated transport inhibited)

pibrentasvir + seladelpar

caution advised: combo may incr. seladelpar levels, risk of adverse effects (BCRP-mediated transport inhibited)

• sirolimus topical
Mavyret (glecaprevir/ pibrentasvir)

+

sirolimus topical

2 interactions

Caution Advised

glecaprevir + sirolimus topical

caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metab. inhibited)

pibrentasvir + sirolimus topical

caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metab. inhibited)

• somatropin
Mavyret (glecaprevir/ pibrentasvir)

+

somatropin

1 interaction

Caution Advised

glecaprevir + somatropin

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• sorafenib
Mavyret (glecaprevir/ pibrentasvir)

+

sorafenib

2 interactions

Caution Advised

glecaprevir + sorafenib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

pibrentasvir + sorafenib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• sotagliflozin
Mavyret (glecaprevir/ pibrentasvir)

+

sotagliflozin

2 interactions

Caution Advised

glecaprevir + sotagliflozin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + sotagliflozin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• sparsentan
Mavyret (glecaprevir/ pibrentasvir)

+

sparsentan

2 interactions

Caution Advised

glecaprevir + sparsentan

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited; BCRP-mediated transport possibly inhibited)

pibrentasvir + sparsentan

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited; BCRP-mediated transport possibly inhibited)

• stiripentol
Mavyret (glecaprevir/ pibrentasvir)

+

stiripentol

2 interactions

Caution Advised

glecaprevir + stiripentol

caution advised: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. possibly induced; BCRP-mediated transport possibly inhibited; P-gp-mediated transport possibly inhibited)

pibrentasvir + stiripentol

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport possibly inhibited; P-gp-mediated transport possibly inhibited)

• sulfasalazine
Mavyret (glecaprevir/ pibrentasvir)

+

sulfasalazine

2 interactions

Caution Advised

glecaprevir + sulfasalazine

caution advised: combo may incr. sulfasalazine levels, risk of adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport inhibited)

pibrentasvir + sulfasalazine

caution advised: combo may incr. sulfasalazine levels, risk of adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport inhibited)

• suvorexant
Mavyret (glecaprevir/ pibrentasvir)

+

suvorexant

2 interactions

Caution Advised

glecaprevir + suvorexant

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

pibrentasvir + suvorexant

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• suzetrigine
Mavyret (glecaprevir/ pibrentasvir)

+

suzetrigine

1 interaction

Caution Advised

glecaprevir + suzetrigine

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• tafamidis
Mavyret (glecaprevir/ pibrentasvir)

+

tafamidis

2 interactions

Caution Advised

glecaprevir + tafamidis

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited)

pibrentasvir + tafamidis

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• tazemetostat
Mavyret (glecaprevir/ pibrentasvir)

+

tazemetostat

1 interaction

Caution Advised

glecaprevir + tazemetostat

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• tecovirimat
Mavyret (glecaprevir/ pibrentasvir)

+

tecovirimat

1 interaction

Caution Advised

glecaprevir + tecovirimat

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• tedizolid phosphate
Mavyret (glecaprevir/ pibrentasvir)

+

tedizolid phosphate

2 interactions

Caution Advised

glecaprevir + tedizolid phosphate

caution advised w/ oral tedizolid; IV tedizolid use OK: combo may incr. glecaprevir levels, risk of adverse effects (gut BCRP-mediated transport inhibited)

pibrentasvir + tedizolid phosphate

caution advised w/ oral tedizolid; IV tedizolid use OK: combo may incr. pibrentasvir levels, risk of adverse effects (gut BCRP-mediated transport inhibited)

• telmisartan
Mavyret (glecaprevir/ pibrentasvir)

+

telmisartan

2 interactions

Caution Advised

glecaprevir + telmisartan

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

pibrentasvir + telmisartan

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• telotristat ethyl
Mavyret (glecaprevir/ pibrentasvir)

+

telotristat ethyl

1 interaction

Caution Advised

glecaprevir + telotristat ethyl

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• teriflunomide
Mavyret (glecaprevir/ pibrentasvir)

+

teriflunomide

2 interactions

Caution Advised

glecaprevir + teriflunomide

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + teriflunomide

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• tezacaftor/ivacaftor
Mavyret (glecaprevir/ pibrentasvir)

+

tezacaftor/ ivacaftor

2 interactions

Caution Advised

glecaprevir + tezacaftor/ ivacaftor

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + tezacaftor/ ivacaftor

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• ticagrelor
Mavyret (glecaprevir/ pibrentasvir)

+

ticagrelor

2 interactions

Caution Advised

glecaprevir + ticagrelor

caution advised: combo may incr. levels of both drugs, risk of dyspnea, bleeding, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

pibrentasvir + ticagrelor

caution advised: combo may incr. levels of both drugs, risk of dyspnea, bleeding, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• tipranavir
Mavyret (glecaprevir/ pibrentasvir)

+

tipranavir

2 interactions

Caution Advised

glecaprevir + tipranavir

caution advised: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy; may incr. tipranavir levels, risk of adverse effects (hepatic transport inhibited, P-gp-mediated transport induced; P-gp-mediated transport inhibited)

pibrentasvir + tipranavir

caution advised: combo may incr. or decr. pibrentasvir levels, incr. risk of adverse effects or decr. efficacy; may incr. tipranavir levels, risk of adverse effects (P-gp-mediated transport altered)

• tocilizumab
Mavyret (glecaprevir/ pibrentasvir)

+

tocilizumab

1 interaction

Caution Advised

glecaprevir + tocilizumab

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

• topiramate
Mavyret (glecaprevir/ pibrentasvir)

+

topiramate

1 interaction

Caution Advised

glecaprevir + topiramate

caution advised, especially w/ topiramate doses >200 mg/day: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• tovorafenib
Mavyret (glecaprevir/ pibrentasvir)

+

tovorafenib

1 interaction

Caution Advised

glecaprevir + tovorafenib

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. induced)

• trazodone
Mavyret (glecaprevir/ pibrentasvir)

+

trazodone

2 interactions

Caution Advised

glecaprevir + trazodone

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + trazodone

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• trimethoprim
Mavyret (glecaprevir/ pibrentasvir)

+

trimethoprim

2 interactions

Caution Advised

glecaprevir + trimethoprim

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + trimethoprim

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• trofinetide
Mavyret (glecaprevir/ pibrentasvir)

+

trofinetide

1 interaction

Caution Advised

glecaprevir + trofinetide

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport possibly inhibited)

• tucatinib
Mavyret (glecaprevir/ pibrentasvir)

+

tucatinib

2 interactions

Caution Advised

glecaprevir + tucatinib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + tucatinib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• turmeric
Mavyret (glecaprevir/ pibrentasvir)

+

turmeric

2 interactions

Caution Advised

glecaprevir + turmeric

caution advised w/ oral turmeric: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (BCRP-mediated transport inhibited, P-gp-mediated transport altered)

pibrentasvir + turmeric

caution advised w/ oral turmeric: combo may incr. or decr. pibrentasvir levels, incr. risk of adverse effects or decr. efficacy (BCRP-mediated transport inhibited, P-gp-mediated transport altered)

• uridine triacetate
Mavyret (glecaprevir/ pibrentasvir)

+

uridine triacetate

2 interactions

Caution Advised

glecaprevir + uridine triacetate

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (gut P-gp-mediated transport possibly inhibited)

pibrentasvir + uridine triacetate

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (gut P-gp-mediated transport possibly inhibited)

• vaborbactam
Mavyret (glecaprevir/ pibrentasvir)

+

vaborbactam

2 interactions

Caution Advised

glecaprevir + vaborbactam

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. possibly induced, P-gp-mediated transport possibly induced)

pibrentasvir + vaborbactam

caution advised: combo may decr. pibrentasvir levels, efficacy (P-gp-mediated transport possibly induced)

• vadadustat
Mavyret (glecaprevir/ pibrentasvir)

+

vadadustat

2 interactions

Caution Advised

glecaprevir + vadadustat

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited, hepatic transport inhibited)

pibrentasvir + vadadustat

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited)

• valbenazine
Mavyret (glecaprevir/ pibrentasvir)

+

valbenazine

2 interactions

Caution Advised

glecaprevir + valbenazine

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + valbenazine

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• vamorolone
Mavyret (glecaprevir/ pibrentasvir)

+

vamorolone

1 interaction

Caution Advised

glecaprevir + vamorolone

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metab. possibly induced)

• vandetanib
Mavyret (glecaprevir/ pibrentasvir)

+

vandetanib

2 interactions

Caution Advised

glecaprevir + vandetanib

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

pibrentasvir + vandetanib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• vanzacaftor/tezacaftor/deutivacaftor
Mavyret (glecaprevir/ pibrentasvir)

+

vanzacaftor/ tezacaftor/ deutivacaftor

2 interactions

Caution Advised

glecaprevir + vanzacaftor/ tezacaftor/ deutivacaftor

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport possibly inhibited, P-gp-mediated transport possibly inhibited)

pibrentasvir + vanzacaftor/ tezacaftor/ deutivacaftor

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport possibly inhibited, P-gp-mediated transport possibly inhibited)

• velpatasvir
Mavyret (glecaprevir/ pibrentasvir)

+

velpatasvir

2 interactions

Caution Advised

glecaprevir + velpatasvir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (hepatic transport inhibited, gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited)

pibrentasvir + velpatasvir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited)

• vemurafenib
Mavyret (glecaprevir/ pibrentasvir)

+

vemurafenib

2 interactions

Caution Advised

glecaprevir + vemurafenib

caution advised: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

pibrentasvir + vemurafenib

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• verapamil
Mavyret (glecaprevir/ pibrentasvir)

+

verapamil

2 interactions

Caution Advised

glecaprevir + verapamil

caution advised: combo may incr. verapamil levels, risk of hypotension, bradycardia, AV block, other adverse effects; may incr. glecaprevir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

pibrentasvir + verapamil

caution advised: combo may incr. verapamil levels, risk of hypotension, bradycardia, AV block, other adverse effects; may incr. pibrentasvir levels, risk of adverse effects (hepatic metab. inhibited; P-gp-mediated transport inhibited)

• voclosporin
Mavyret (glecaprevir/ pibrentasvir)

+

voclosporin

2 interactions

Caution Advised

glecaprevir + voclosporin

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, hepatic transport inhibited)

pibrentasvir + voclosporin

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• vorasidenib
Mavyret (glecaprevir/ pibrentasvir)

+

vorasidenib

2 interactions

Caution Advised

glecaprevir + vorasidenib

caution advised: combo may incr. vorasidenib levels, risk of adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited; hepatic metab. possibly induced)

pibrentasvir + vorasidenib

caution advised: combo may incr. vorasidenib levels, risk of adverse effects (hepatic metab. inhibited)

• xanomeline
Mavyret (glecaprevir/ pibrentasvir)

+

xanomeline

2 interactions

Caution Advised

glecaprevir + xanomeline

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (gut P-gp-mediated transport possibly inhibited)

pibrentasvir + xanomeline

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (gut P-gp-mediated transport possibly inhibited)

• zonisamide
Mavyret (glecaprevir/ pibrentasvir)

+

zonisamide

2 interactions

Caution Advised

glecaprevir + zonisamide

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

pibrentasvir + zonisamide

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)